Acuity Inc. (NYSE: AYI) insider plans sale of 4,974 shares

Rhea-AI Filing Summary

An affiliate of Acuity Inc. filed a notice of proposed sale of 4,974 shares of common stock, with an aggregate market value of $1,538,110.02. These shares are to be sold through Merrill Lynch on the NYSE, with an approximate sale date of January 28, 2026.

The issuer had 30,662,621 shares of common stock outstanding. Recently acquired shares included 897 shares from an employee stock option exercise and 4,077 shares from vesting of restricted stock and performance share awards granted under the issuer’s equity compensation plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	4974	1538110.02	30662621	01/28/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/28/2026	Exercise of employee stock options	ACUITY INC. (DE)			897	01/28/2026	Broker assisted cashless exercise
Common stock	10/26/2024	Vesting of restricted stock unit award	ACUITY INC. (DE)			626	10/26/2024	Granted as part of issuer equity compensation plan
Common stock	10/25/2024	Vesting of performance share award	ACUITY INC. (DE)			3451	10/25/2024	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What share sale is disclosed for AYI in this Form 144 filing?

The filing discloses a planned sale of 4,974 shares of Acuity Inc. common stock. These shares have an aggregate market value of $1,538,110.02 and are expected to be sold on the NYSE through Merrill Lynch.

Which broker will handle the planned AYI share sale and on which exchange?

The planned sale of 4,974 Acuity Inc. common shares will be handled by Merrill Lynch, located at 225 Liberty St, New York. The shares are expected to be sold on the New York Stock Exchange (NYSE) on or around January 28, 2026.

How many Acuity (AYI) shares are outstanding compared to the planned sale?

The issuer reported 30,662,621 shares of common stock outstanding. The planned sale covers 4,974 shares, a small fraction of the outstanding total, as disclosed in the Form 144 notice for a proposed sale on the NYSE through Merrill Lynch.

How were the AYI shares to be sold under this Form 144 acquired?

Recently related acquisitions include 897 shares from the exercise of employee stock options and 4,077 shares from vesting of restricted stock unit and performance share awards. These awards were granted under the issuer’s equity compensation plan and later became available as common stock.

What is the approximate date for the planned AYI stock sale in this notice?

The planned sale of 4,974 Acuity Inc. common shares lists an approximate sale date of January 28, 2026. This date appears in the Form 144 securities information section, alongside the NYSE as the named securities exchange for the transaction.

What does the Form 144 representation say about undisclosed adverse information?

The person for whose account the shares are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, as part of the standard certification language included with the signed notice.